Direct to Consumer

As the nation prepares to return to work and open up the economy in the midst of the COVID-19 pandemic without an available vaccine or effective therapy, testing and contact tracing will be essential tools to contain and limit the spread of the virus. To address these issues, researchers from across MGB and collaborators from across Boston, the US and the world came together to identify solutions.

COVID-19 Rapid Tests

In response to the urgent public health need for accurate, effective, low-cost, and scalable COVID-19 testing technology, the Direct-To-Consumer (DTC) working group within the Mass General Brigham (MGB) Center for COVID-19 Innovation was tasked with identifying viable diagnostic solutions with potential for use as a DTC product. To identify potential products, we performed a deep horizon scan for antigen and serology based diagnostics and down selected to the most promising. Product evaluations are based entirely on company provided data. Those that passed our first scoring algorithm based on Specificity and Sensitivity data were then further evaluated by our second scoring algorithm based on additional technical specifications in combination with data about the company and distribution capacity. The results of these efforts are displayed in the table below. All blank fields represent information we were unable to obtain. The performance metrics for some of the high scoring products are currently being validated in-house through the Diagnostics Accelerator. Once complete, this data will be made available. 

Antibody Test Results

If your product is not on our list or has incomplete or incorrect information, please fill out this questionnaire to provide us with details. If you need to reach us directly, please send your inquiry to covid_innovation_diagnostics@partners.org

Horizon Scan: Workflow

Infographic: Eileen Debenham, Go Big Branding

Horizon Scan: Methodology

A total of 303 candidate tests were identified through a deep horizon scan utilizing existing sources including FIND, FDA, Johns Hopkins University, RTT News and ARTG. Initial screening removed 125 tests as duplicates (different sources provided slightly different company or product names for the same test). Additional triage identified 90 tests (17 antigen and 73 antibody) with potential for use outside of a healthcare setting (e.g. specimens could be easily collected and specialized lab equipment was not required for performance or interpretation of the test) and were either currently in-use or had significant regulatory activity. For these potentially viable DTC tests, sensitivity and specificity values were obtained from publicly available information. For antigen tests, publicly available information was severely limited, likely due to the early stage of development of these products, so further evaluation was restricted to antibody tests.  Application of Score 1 (see table 1) resulted in 25 tests with Score 1 ≥ 1, which were further subjected to a deep-dive gathering of information, including requesting additional information from the companies. Based on this information, Score 2 (see table 1) was applied to provide a scored list of tests for in-house evaluation by the Diagnostics Accelerator and Validation working group.  
Table 1: Scoring Metrics

Contact Tracing Assessment

Effective contact tracing is an essential aspect of managing and containing the spread of a highly contagious disease like COVID-19. Proliferation of smartphones in the population has enabled the development of solutions that can aid manual contact tracing efforts. Such solutions can provide valuable information that can be used by users and public health officials for rapid and accurate contact tracing. However, these solutions capture sensitive data (e.g. proximity, location, phone number) and therefore present a risk to privacy.  We performed a detailed assessment of more than 40 solutions that fell in three categories: smartphone apps, online surveys and data aggregators. These solutions were assessed for characteristics like type of data captured, privacy policy, location tracing requirement, development status and geographical availability. We found significant differences between solutions and identified several limitations that can be addressed to improve the sensitivity and specificity of the information.  In order for technology-based contact tracing to be successful, solutions will have to (1) be adopted by a large portion of the population (around 40-60%), (2) be based on strong privacy and security standards, (3) minimize fragmentation and encourage data sharing, and (4) capture confirmation of diagnosis.

The information contained on this website is provided by the MGB Center for COVID Innovation (MGB-CCI) and is for general information purposes only and is not intended to be used as a reference for funding or grant proposals. In no case does the inclusion or exclusion of products or information contained on this website represent an endorsement nor should it be interpreted as judgement on validity or legitimacy of tests. While we attempt to keep the information current and correct, MGB-CCI cannot and does not guarantee the accuracy, reliability, suitability or completeness of the information and products contained on the website for any purpose. Any reliance placed on such information is therefore solely at your own risk.

In no case will MGB-CCI be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of or in connection with the use of this website.

Links contained within this website direct to other websites that are not maintained by MGB-CCI. We have no control over the nature, content and availability of those sites and the inclusion of these links does not necessarily imply a recommendation or endorsement of the views expressed within them.